Raw Materials & Excipients Management – Page 20

Supplier change not evaluated during post-approval change review – preventing batch rejection and recalls

Recognizing early signs of potential issues related to unassessed supplier changes is critical for timely intervention. Key symptoms might include:Click to read the full article.

Audit response ineffective during routine supplier audit – audit CAPA remediation framework

Framework for Addressing Ineffective Audit Responses During Supplier Assessments In a fast-paced pharmaceutical environment, the integrity of raw materials directly influences product quality, regulatory compliance, and operational efficiency. An ineffective…

Specification change not communicated during routine operations – regulatory expectations for material changes

Monitoring for indicators of specification changes is crucial. The following are common symptoms that might indicate uncommunicated changes:Click to read the full article.

Vendor change implemented without approval during regulatory inspection – inspection questions regulators ask

Investigation of Unapproved Vendor Changes During Regulatory Inspections In the complex landscape of pharmaceutical manufacturing, unexpected vendor changes can have significant consequences, especially when such alterations occur without the necessary…

Change impact underestimated during routine operations – preventing batch rejection and recalls

Identifying early symptoms of change impact is crucial. These signals may manifest during various stages of production or testing, and recognizing them can prevent further complications:Click to read the full…

Inadequate vendor qualification during supply disruption – audit CAPA remediation framework

Recognizing symptoms or signals that indicate inadequate vendor qualification is crucial for early intervention. Common indicators include:Click to read the full article.

Specification change not communicated during supplier change – risk-based change impact assessment

Personnel in manufacturing, quality control (QC), and quality assurance (QA) often notice symptoms that indicate potential issues arising from specification changes that haven’t been appropriately communicated:Click to read the full…

Supplier audit findings escalated during supplier onboarding – how to prevent repeat supplier failures

Supplier audit issues can manifest in several ways. Recognizing these symptoms early can make a significant difference in mitigating risks. Below are common signals indicating potential supplier-related concerns:Click to read…

Unapproved material substitution during deviation investigation – CAPA to prevent repeat failures

Identifying signs of unapproved material substitution is crucial to mitigating risks associated with product quality and compliance. Common symptoms that may indicate a problem during manufacturing or lab operations include:Click…

Supplier audit findings escalated during supplier onboarding – inspection questions regulators ask

Investigating Escalated Supplier Audit Findings During Onboarding In pharmaceutical manufacturing, effective vendor qualification and supplier audits are critical components in maintaining quality and compliance. However, supplier audit findings can sometimes…

Change control documentation gaps during post-approval change review – inspection questions regulators ask

Recognizing early warning signs of inadequacies in change control is vital for timely action. Common symptoms include:Click to read the full article.

Quality agreement gaps during supply disruption – supplier risk classification strategy

Recognizing early symptoms of quality agreement gaps during supply disruptions is pivotal. Symptoms may manifest as deviations from established quality standards, which can include:Click to read the full article.